Press Releases

PORTLAND, Ore., Feb. 13, 2020 /PRNewswire/ -- STD Carriers Disease Control and Prevention Services unveiled the latest version of their online sexually transmitted disease (STD) fighting machine by giving STDCarriers.com a mobile friendly facelift just in time for Valentine's Day. The renovation is part of an effort to improve the usability of STD Carriers for those loo

LOS ANGELES, Feb. 13, 2020 /PRNewswire/ -- Fresh off the catwalk at Once Upon a Runway: A Toy Story benefiting St. Jude's a

SAN DIEGO, Feb. 13, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the results of the study, "

EMERYVILLE, Calif., Feb. 13, 2020 /PRNewswire/ -- Amyris, Inc. (NASDAQ: AMRS), a global science and technology leader of pure, sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that Han Kieftenbeld is joining the company as Chief Financial Officer effective

NEW YORK, Feb. 13, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the launch of its FDA approved non-opioid drug Strontium89 (Strontium Chloride Sr-89 Injection, USP

PHOENIX, Feb. 13, 2020 /PRNewswire/ -- 

CLEVELAND, Feb. 13, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2019 financial results.

SAN JUAN, Puerto Rico, Feb. 13, 2020 /PRNewswire/ -- Triple-S Management Corporation (NYSE: GTS) today announced that it plans to release financial results for the fourth quarter ended December 31, 2019 before the market opens on Thursday, February 27, 2020. Roberto García-Rodríguez, President and

DUBLIN, Feb. 13, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2019 financial results on Thursday, February 27, 2020. The Company will also host a conference call beginning at 8:30 a.m. (EST).

JERSEY CITY, N.J., Feb. 13, 2020 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has completed patient enrollment in its global Phase 3 VANISH-306 study to evaluate the safety and efficacy of oral ibrexafungerp as a treatment